> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Treace Targets A $700 Million Market Expansion While Lower-Priced Products Weigh On Revenue
- URL: https://www.bullished.co/treace-targets-a-700-million-market-expansion-while-lower-priced-products-weigh-on-revenue-24dc3b99/
- Published: 2026-11-06T14:06:02.000Z
- Updated: 2026-11-06T14:06:02.000Z
- Description: Management expects fourth-quarter growth as surgeons adopt a wider portfolio, with only incremental additions to the sales force.
- Author: Matteo Parrino
- Tags: Earnings, TMCI, Industry: Healthcare

[Treace Medical Concepts](https://www.bullished.co/tag/tmci/), which makes instruments and implants for bunion and related foot surgery, expects its 2026 product introductions to open approximately $700 million in additional addressable markets—even as cheaper products weigh on sales. On Friday's third-quarter earnings call, Chief Executive Officer John Treace laid out a strategy to sell more into operations its representatives already attend, rather than build a much larger sales force.

## More Cases, Less Revenue

The tension is already visible in the results. Third-quarter revenue was [$48.3 million](https://finance.yahoo.com/markets/stocks/articles/treace-medical-concepts-q3-earnings-122146577.html?ref=bullished.co), down 4% from a year earlier, despite the double-digit case-volume growth Treace described. Chief Financial Officer Mark Hair attributed the sales decline mainly to a greater mix of lower-priced minimally invasive products and fewer bunion procedure kits sold.

Stocking distributors also affected the comparison. Last year's third quarter included initial stocking orders that did not recur this year, Hair said. Excluding those customers, bunion kit volume increased and revenue grew about 5%; management expects the effect of distributor orders to diminish significantly in the fourth quarter.

A wider product selection does not necessarily restore historical selling prices. Treace told an analyst from BTIG that "overall ASPs or revenue per case may come down a bit" as the portfolio expands. More complex midfoot and rearfoot operations can include multiple Treace technologies and generate higher revenue per case, he said, but some newer offerings sell for less than its original bunion system.

Hair narrowed the annual revenue outlook to $206 million–$210 million from $204 million–$212 million. The new range represents a decline of 3% to 1% from 2025\. Asked by a Stifel analyst why the upper bound fell, Hair said management's fourth-quarter view was unchanged and the quarter's modest outperformance did not warrant a different annual outlook. Management still expects revenue growth in its seasonally strongest fourth quarter.

## Selling Beyond The Bunion Operation

The commercial strategy starts with the surgeon, not a new sales territory. Treace said its original bunion and midfoot systems covered around 30% of the average customer's reconstructive foot and ankle surgery volume about a year ago. With the bunion systems introduced in the third quarter of 2025 and the 2026 additions, management estimates it can now address 80% or more.

The company's core product is the Lapiplasty 3D Bunion Correction System. Its broader range includes minimally invasive bunion systems, great-toe fusion products, midfoot correction systems, patient-specific cutting guides and sterile disposable instruments. Employee sales representatives generated about 80% of revenue in 2025; the field sales team had 297 members as of December 31, 2025.

Approximately 45% of Lapiplasty surgeons had used at least one of the three newer bunion systems through the third quarter, compared with 40% in the second quarter. Adoption also works in the other direction: approximately 30% of surgeons who became customers through those newer systems now use the original bunion products, Treace said.

An analyst from Lake Street asked how far that adoption could extend. Treace said the goal goes beyond getting surgeons to try one system: management wants customers using several products across their practices. When Stifel pressed on repeat buying rather than initial trials, Treace described the repeat-customer rate as "pretty high" and said use of multiple systems was increasing.

## Screws, Grafts And Smaller-Toe Surgery

The approximately $700 million figure is management's estimate of additional addressable market, not a sales forecast. Part of that expansion comes from products that can replace competing supplies within an existing operation.

SuperBite compression screws, fully launched in the third quarter, are designed to eliminate drilling before screw placement. Treace said they have brought the company into additional procedures across the foot and ankle, with some surgeons also using other Treace products in those cases.

The company has added HyperPlate XM implants for midfoot and hindfoot bone fusions, using a titanium compression plate and locking screws. Its VitaFuse synthetic bone graft complements tissue-based CordaFuse grafts and allograft wedges. Cartoblaster disposable instruments attach to a powered surgical saw to remove cartilage before fusion.

Management estimates that those four offerings together expand its U.S. addressable market by $400 million. It expects full commercialization of VitaFuse and Cartoblaster during the fourth quarter.

Treace also announced initial surgical cases with its minimally invasive system for bunionettes—painful deformities of the fifth metatarsal bone. Management estimates bunionettes affect 5% to 10% of U.S. adults; surgery can accompany a bunion correction or be performed separately. Full commercialization is anticipated in the first quarter of 2027, when the company also anticipates launching its Lightning platform for faster, more controlled bunion correction.

## A Bigger Bag, Restrained Spending

BTIG questioned whether the launch schedule could distract representatives during the busy surgical season. Treace acknowledged that "there are a lot of new technologies coming into the reps' hands" and said the company is investing in training and has hired representatives with foot-and-ankle experience at competitors.

The staffing plan remains incremental. Representatives can offer screws, grafts and disposable instruments during cases they already support, replacing competitors' products, Treace said. Hair added that commission costs would track revenue and that management was "not anticipating dramatic changes to our OpEx."

Third-quarter operating expenses fell 10% to [$49.9 million](https://www.globenewswire.com/news-release/2026/11/06/3397449/0/en/treace-medical-concepts-reports-third-quarter-2026-financial-results.html?ref=bullished.co) from $55.4 million a year earlier. Gross margin reached 79.5%, compared with 79.1%. Net loss narrowed 23% to [$12.6 million](https://finance.yahoo.com/markets/stocks/articles/treace-medical-concepts-q3-earnings-122146577.html?ref=bullished.co), or $0.19 per share, from $16.3 million, or $0.26 per share.

Adjusted earnings before interest, taxes, depreciation and amortization were positive $0.3 million, versus a $2.6 million loss a year earlier. Management now expects an annual loss on that measure of $1 million–$2 million, compared with a $3.9 million loss in 2025.

Cash use for the year to date fell 53%, or $9.7 million. Cash, cash equivalents and marketable securities totaled $39.8 million on September 30, 2026, and management reiterated its expectation to reduce full-year cash use by approximately 50%.

Hair plans to give 2027 guidance on the fourth-quarter earnings call, after assessing peak-season case volumes and gaining more experience with the new products.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Treace Medical Concepts: Q3 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/treace-medical-concepts-q3-earnings-122146577.html?ref=bullished.co) — Associated Press
- [Earnings To Watch: Treace Medical Concepts Inc (TMCI) Q3 2026 -- GF Value Sees 50% Upside](https://finance.yahoo.com/markets/stocks/articles/earnings-watch-treace-medical-concepts-123725270.html?ref=bullished.co) — Yahoo Finance
- [Treace Medical Concepts Reports Third Quarter 2026](https://www.globenewswire.com/news-release/2026/11/06/3397449/0/en/treace-medical-concepts-reports-third-quarter-2026-financial-results.html?ref=bullished.co) — globenewswire.com
- [Treace Announces First Surgical Cases with the](https://www.globenewswire.com/news-release/2026/11/06/3397447/0/en/treace-announces-first-surgical-cases-with-the-tailorplasty-mis-tailor-s-bunion-correction-system.html?ref=bullished.co) — globenewswire.com
- [Treace to Present at the Stifel 2026 Healthcare Conference](https://www.globenewswire.com/news-release/2026/11/03/3394785/0/en/treace-to-present-at-the-stifel-2026-healthcare-conference.html?ref=bullished.co) — globenewswire.com

### More on Treace Medical Concepts

- [Treace Cuts Its Quarterly Loss 23% To $12.6 Million As Revenue Slips 4%](https://www.bullished.co/treace-cuts-its-quarterly-loss-23-to-12-6-million-as-revenue-slips-4-ad2bae0c/)

[All Treace Medical Concepts (TMCI) coverage →](https://www.bullished.co/tag/tmci/)